Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 8,996 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the sale, the chief financial officer now owns 173,583 shares in the company, valued at $2,301,710.58. The trade was a 4.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The shares were sold at an average price of $10.85, for a total value of $17,208.10.

Evolus Stock Performance

Shares of Evolus stock opened at $13.25 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market cap of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The company has a 50 day moving average of $13.36 and a 200-day moving average of $13.91. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on EOLS shares. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. acquired a new position in shares of Evolus during the 3rd quarter worth $212,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Evolus in the 3rd quarter valued at approximately $940,000. Intech Investment Management LLC bought a new position in shares of Evolus during the third quarter valued at $228,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after purchasing an additional 265,635 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Evolus in the third quarter worth $191,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.